Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABLe: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma
NCT04717700Phase 2Active, not recruiting
- Start
- Aug 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of selinexor in multiple myeloma (MM). Started Aug 2021; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04717700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04717700.